Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions
HRMY Stock Forecast
Harmony Biosciences stock forecast is as follows: an average price target of $45.33 (represents a 32.54% upside from HRMY’s last price of $34.20) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
HRMY Price Target
HRMY Analyst Ratings
Buy
Harmony Biosciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 30, 2024 | Corinne Jenkins | Goldman Sachs | $28.00 | $41.49 | -32.51% | -18.13% |
Oct 10, 2024 | Graig Suvannavejh | Mizuho Securities | $52.00 | $33.60 | 54.76% | 52.05% |
Sep 10, 2024 | Ashwani Verma | UBS | $56.00 | $36.89 | 51.80% | 63.74% |
Aug 08, 2024 | Graig Suvannavejh | Mizuho Securities | $42.00 | $33.55 | 25.19% | 22.81% |
Jun 24, 2024 | Francois Brisebois | Oppenheimer | $56.00 | $30.39 | 84.27% | 63.74% |
May 01, 2024 | Ami Fadia | Needham | $52.00 | $30.37 | 71.22% | 52.05% |
Apr 30, 2024 | Danielle Brill | Raymond James | $37.00 | $30.91 | 19.70% | 8.19% |
Oct 14, 2022 | Chris Howerton | Jefferies | $61.00 | $47.63 | 28.07% | 78.36% |
Harmony Biosciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 2 | 7 |
Avg Price Target | - | $40.00 | $46.14 |
Last Closing Price | $34.20 | $34.20 | $34.20 |
Upside/Downside | -100.00% | 16.96% | 34.91% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 30, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
Oct 30, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Oct 30, 2024 | Goldman Sachs | Sell | Sell | Hold |
Oct 29, 2024 | UBS | Buy | Buy | Hold |
Oct 29, 2024 | Raymond James | Underperform | Underperform | Hold |
Oct 02, 2024 | UBS | Buy | Buy | Hold |
Sep 12, 2024 | Needham | Buy | Buy | Hold |
Sep 10, 2024 | UBS | Buy | Buy | Hold |
Sep 10, 2024 | Needham | Underperform | Underperform | Hold |
Sep 09, 2024 | UBS | Buy | Initialise | |
Aug 06, 2024 | Needham | Buy | Buy | Hold |
Jun 24, 2024 | Citigroup | Buy | Buy | Hold |
Jun 24, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Jun 21, 2024 | Needham | Buy | Buy | Hold |
Jun 21, 2024 | Citigroup | Underperform | Underperform | Hold |
Jun 20, 2024 | Citigroup | Buy | Initialise | |
Apr 30, 2024 | Raymond James | Outperform | Outperform | Hold |
Apr 30, 2024 | Needham | Buy | Buy | Hold |
Apr 30, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
Mar 28, 2024 | Needham | Buy | Buy | Hold |
Mar 28, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
Feb 22, 2024 | Needham | Buy | Buy | Hold |
Oct 14, 2022 | Jefferies | Buy | Buy | Hold |
Oct 14, 2022 | Jefferies | Buy | Upgrade | |
Apr 26, 2022 | Zacks Investment Research | Hold | Upgrade |
Harmony Biosciences Financial Forecast
Harmony Biosciences Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $160.27M | $134.22M | $119.13M | $128.31M | $117.21M | $107.03M | $85.31M | $91.21M | $80.73M | $73.82M | $59.67M | $56.29M | $45.61M |
Avg Forecast | $277.53M | $265.66M | $246.78M | $220.79M | $232.97M | $220.31M | $204.70M | $183.83M | $198.60M | $184.07M | $172.53M | $154.10M | $169.02M | $147.83M | $142.01M | $120.14M | $127.66M | $113.59M | $100.73M | $88.55M | $89.53M | $79.90M | $68.83M | $57.20M | $51.89M | $40.00M |
High Forecast | $289.72M | $277.33M | $257.61M | $230.48M | $243.20M | $229.99M | $213.69M | $194.45M | $203.28M | $184.36M | $172.53M | $160.87M | $169.67M | $156.89M | $148.25M | $125.41M | $133.27M | $113.59M | $100.73M | $88.55M | $89.53M | $79.90M | $68.83M | $57.20M | $51.89M | $40.00M |
Low Forecast | $268.36M | $256.88M | $238.62M | $213.49M | $225.27M | $213.03M | $197.94M | $178.22M | $192.04M | $183.77M | $172.53M | $149.01M | $168.37M | $139.32M | $137.32M | $116.17M | $123.44M | $113.59M | $100.73M | $88.55M | $89.53M | $79.90M | $68.83M | $57.20M | $51.89M | $40.00M |
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 0.95% | 0.99% | 1.01% | 1.03% | 1.06% | 0.96% | 1.02% | 1.01% | 1.07% | 1.04% | 1.08% | 1.14% |
Forecast
Harmony Biosciences EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $64.51M | $46.90M | $46.49M | $47.69M | $18.02M | $39.21M | $32.75M | $33.42M | $-5.85M | $20.82M | $12.06M | $12.14M | $10.82M |
Avg Forecast | $3.67M | $3.52M | $3.27M | $2.92M | $3.08M | $2.92M | $2.71M | $2.43M | $2.63M | $2.44M | $2.28M | $40.29M | $2.24M | $1.96M | $1.88M | $36.63M | $34.72M | $1.04M | $926.09K | $28.96M | $823.08K | $734.59K | $632.84K | $525.89K | $477.04K | $8.66M |
High Forecast | $3.84M | $3.67M | $3.41M | $3.05M | $3.22M | $3.05M | $2.83M | $2.57M | $2.69M | $2.44M | $2.28M | $48.35M | $2.25M | $2.08M | $1.96M | $43.96M | $41.67M | $1.04M | $926.09K | $34.75M | $823.08K | $734.59K | $632.84K | $525.89K | $477.04K | $10.39M |
Low Forecast | $3.55M | $3.40M | $3.16M | $2.83M | $2.98M | $2.82M | $2.62M | $2.36M | $2.54M | $2.43M | $2.28M | $32.23M | $2.23M | $1.84M | $1.82M | $29.30M | $27.78M | $1.04M | $926.09K | $23.16M | $823.08K | $734.59K | $632.84K | $525.89K | $477.04K | $6.93M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.96% | 24.94% | 1.27% | 1.37% | 17.26% | 42.34% | 1.13% | 40.61% | -7.96% | 32.90% | 22.94% | 25.45% | 1.25% |
Forecast
Harmony Biosciences Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.46M | $34.30M | $29.48M | $48.51M | $87.94M | $23.53M | $21.48M | $22.71M | $-9.62M | $14.12M | $7.39M | $-208.00K | $1.91M |
Avg Forecast | $69.92M | $66.23M | $60.68M | $51.51M | $51.21M | $48.25M | $44.11M | $36.99M | $39.75M | $38.63M | $-96.86K | $26.43M | $41.95M | $38.67M | $35.37M | $24.03M | $23.60M | $5.97M | $25.89M | $18.99M | $20.52M | $16.11M | $10.17M | $97.50M | $4.41M | $1.53M |
High Forecast | $73.91M | $70.01M | $64.14M | $54.45M | $54.13M | $51.01M | $46.62M | $46.97M | $53.55M | $38.69M | $-92.70K | $31.72M | $44.79M | $46.41M | $37.39M | $28.83M | $28.32M | $5.97M | $25.89M | $22.79M | $20.52M | $16.11M | $10.17M | $116.99M | $4.41M | $1.83M |
Low Forecast | $66.92M | $63.39M | $58.07M | $49.29M | $49.01M | $46.18M | $42.21M | $22.90M | $24.84M | $38.58M | $-102.39K | $21.14M | $40.25M | $33.91M | $33.85M | $19.22M | $18.88M | $5.97M | $25.89M | $15.20M | $20.52M | $16.11M | $10.17M | $78.00M | $4.41M | $1.22M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.97% | 1.23% | 2.06% | 14.73% | 0.91% | 1.13% | 1.11% | -0.60% | 1.39% | 0.08% | -0.05% | 1.25% |
Forecast
Harmony Biosciences SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $45.96M | $47.34M | $44.63M | $43.72M | $41.80M | $42.32M | $35.46M | $37.31M | $33.34M | $31.32M | $30.05M | $30.99M | $23.11M |
Avg Forecast | $843.71M | $807.63M | $750.22M | $671.21M | $708.26M | $669.77M | $622.31M | $558.86M | $603.75M | $559.58M | $524.49M | $43.63M | $513.84M | $449.40M | $431.72M | $39.66M | $38.77M | $345.31M | $306.22M | $31.35M | $272.16M | $242.90M | $209.26M | $173.89M | $157.74M | $18.49M |
High Forecast | $880.75M | $843.09M | $783.16M | $700.68M | $739.35M | $699.17M | $649.63M | $591.13M | $617.97M | $560.48M | $524.49M | $52.35M | $515.82M | $476.96M | $450.68M | $47.59M | $46.52M | $345.31M | $306.22M | $37.62M | $272.16M | $242.90M | $209.26M | $173.89M | $157.74M | $22.18M |
Low Forecast | $815.82M | $780.93M | $725.42M | $649.03M | $684.84M | $647.63M | $601.74M | $541.79M | $583.80M | $558.68M | $524.49M | $34.90M | $511.86M | $423.53M | $417.45M | $31.73M | $31.01M | $345.31M | $306.22M | $25.08M | $272.16M | $242.90M | $209.26M | $173.89M | $157.74M | $14.79M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.10% | 0.11% | 1.13% | 1.13% | 0.12% | 0.14% | 1.13% | 0.14% | 0.14% | 0.15% | 0.17% | 0.20% | 1.25% |
Forecast
Harmony Biosciences EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.64 | $0.57 | $0.49 | $0.82 | $1.48 | $0.40 | $0.36 | $0.39 | $-0.17 | $0.25 | $0.13 | $-0.00 | $0.06 |
Avg Forecast | $1.20 | $1.14 | $1.04 | $0.89 | $0.88 | $0.83 | $0.76 | $0.64 | $0.68 | $0.66 | $-0.00 | $0.60 | $0.72 | $0.67 | $0.61 | $0.47 | $0.58 | $0.10 | $0.45 | $0.29 | $0.36 | $0.28 | $0.18 | $-0.03 | $0.08 | $-0.05 |
High Forecast | $1.27 | $1.20 | $1.10 | $0.94 | $0.93 | $0.88 | $0.80 | $0.81 | $0.92 | $0.67 | $-0.00 | $0.60 | $0.77 | $0.80 | $0.64 | $0.50 | $0.62 | $0.10 | $0.45 | $0.29 | $0.36 | $0.28 | $0.18 | $-0.03 | $0.08 | $-0.05 |
Low Forecast | $1.15 | $1.09 | $1.00 | $0.85 | $0.84 | $0.79 | $0.73 | $0.39 | $0.43 | $0.66 | $-0.00 | $0.60 | $0.69 | $0.58 | $0.58 | $0.45 | $0.56 | $0.10 | $0.45 | $0.29 | $0.36 | $0.28 | $0.18 | $-0.03 | $0.08 | $-0.05 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.94% | 1.04% | 1.40% | 14.27% | 0.89% | 1.23% | 1.09% | -0.61% | 1.42% | -4.87% | -0.05% | -1.35% |
Forecast
Harmony Biosciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $2.38 | $33.86 | 1322.69% | Buy |
KROS | Keros Therapeutics | $16.42 | $101.00 | 515.10% | Buy |
INZY | Inozyme Pharma | $2.92 | $16.00 | 447.95% | Buy |
GOSS | Gossamer Bio | $0.85 | $3.75 | 341.18% | Buy |
GPCR | Structure Therapeutics | $29.04 | $99.00 | 240.91% | Buy |
LYRA | Lyra Therapeutics | $0.19 | $0.50 | 163.16% | Hold |
PLRX | Pliant Therapeutics | $13.56 | $35.50 | 161.80% | Buy |
FENC | Fennec Pharmaceuticals | $6.22 | $15.75 | 153.22% | Buy |
SNDX | Syndax Pharmaceuticals | $12.77 | $30.60 | 139.62% | Buy |
IDYA | IDEAYA Biosciences | $25.16 | $53.33 | 111.96% | Buy |
EWTX | Edgewise Therapeutics | $28.74 | $46.25 | 60.93% | Buy |
REPL | Replimune Group | $12.26 | $19.00 | 54.98% | Buy |
RVMD | Revolution Medicines | $44.21 | $65.67 | 48.54% | Buy |
PTGX | Protagonist Therapeutics | $38.96 | $57.33 | 47.15% | Buy |
NUVL | Nuvalent | $80.30 | $114.80 | 42.96% | Buy |
HRMY | Harmony Biosciences | $34.20 | $45.33 | 32.54% | Buy |
JANX | Janux Therapeutics | $54.10 | $70.25 | 29.85% | Buy |
TVTX | Travere Therapeutics | $17.28 | $21.75 | 25.87% | Buy |
VRDN | Viridian Therapeutics | $19.45 | $22.75 | 16.97% | Buy |
KRON | Kronos Bio | $0.94 | $1.00 | 6.38% | Buy |
VRNA | Verona Pharma | $46.19 | $39.50 | -14.48% | Buy |